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Screening without evidence of efficacy
Thyroid ultrasonography is another
example
Editor—I agree with Law’s view of screen-
ing, that screening of unproved value should
not be advocated.1 As a clinical endocrinolo-
gist I often have to deal with patients’ anxie-
ties about non-palpable incidental findings
on thyroid ultrasonography, often per-
formed for wrong or unjustified reasons.
Sometimes patients arrive with already
established surgical complications after
unnecessary thyroid operations.
Although a substantial number of
incidental thyroid nodules may be histologi-
cally malignant,2 their clinical importance
has never been proved. A recent preliminary
study indicates that the progression rate of
non-palpable proved thyroid malignant
nodules to clinically significant lesions may
be very low.3 Thyroid ultrasonography is an
additional example of an often used, often
non-efficacious screening modality that may
lead to “cascade iatrogenesis.”4
Yair Liel head, endocrine service
Soroka University Medical Centre, Beer-Sheva, Israel
liel@bgumail.bgu.ac.il
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Screening uncertainties concern
evidence, efficacy, decisions
Editor—Law argues that encouraging
people to decide for themselves whether to
attend for screening is ducking the issue.1
This is true only if a well founded public
health programme for a specific disease has
not been set up. Then, setting up a
programme, as Law advocates, should be
based on evidence, through rigorous scien-
tific evaluation of efficacy through system-
atic review of high quality trials. Outcomes
assessed should be both mortality and all
associated adverse effects that affect an indi-
vidual person’s quality of life. Good quality
evidence based information should also be
made available to suit all citizens so that they
have a better chance of arriving at an
informed decision with their (equally well
informed) health professional, if desired.
Provision of such evidence takes time.
But the screening industry and the public
are not prepared to wait: mammographic
screening for those aged 40-50 is widely
practised, yet the findings from the AGE
trial of breast screening by mammography
in young women that began in 1991 and
closed in November 2000 are not yet
published. Is there not an ethical obligation
to make these findings public without
further delay?
Encouraging people to decide for them-
selves through provision of better infor-
mation is, however, crucial in well estab-
lished screening programmes such as the
NHS breast screening programme for 50-65
year olds.2 More than a decade of persuasive
information has reinforced the intuitive
appeal of screening early to save your life in
a social and cultural climate that has
blossomed on frequently reiterated beliefs.3 4
Evidence comes a poor second in decision
making in a population not educated to see
the need for fair tests of treatments,
interventions, systems, and processes to
underpin what and what is not offered in
healthcare systems.5
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Summary of responses
Editor—Law’s editorial on screening with-
out evidence of efficacy prompted a predict-
ably substantial number of responses that
were, perhaps not so predictably, mostly
united in their agreement with his objec-
tions to advocating screening of unproved
value.1 He concludes: “For a new drug a rig-
orous set of experimental data must be pre-
sented before it is licensed for use, and until
it is licensed patients cannot obtain it. The
same rigour should apply to medical screen-
ing.”
Most of the responses questioned the
value of screening and threw its potential
cost to the public purse into the equation;
some highlighted that it was harmful. One
correspondent explained what happens if
health authorities advocate screening of
unproved value, as illustrated by primary
prevention of cardiovascular disease in the
United Kingdom, where political and finan-
cial imperatives to screen and treat have
been powerful inducements to change
routine practice.
Two correspondents argued passion-
ately that screening (in the form of breast
awareness and testing for prostate specific
antigen) was a very good thing indeed.
Another took a level view and cited system-
atic reviews to support his own opinion, that
the benefits of screening cannot be deter-
mined.
Others questioned the drug trial anal-
ogy. Randomised controlled trials are
appropriate for testing the safety and
efficacy of drugs, but they are not appropri-
ate for screening. Drug discovery and devel-
opment processes are subject to intellectual
property laws and governmental regulation.
If a pharmaceutical company shows that a
new drug is safe and efficacious in a particu-
lar condition its investment on research and
development costs may well be returned
with patent protection and exclusivity rights
for several years. No patents exist for screen-
ing programmes, and the funding for a
thorough evaluation of their risk and
benefits would therefore have to come from
the public purse.
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Another correspondent cites a case in
US law as an example of a worst case
scenario and asks for rigorous experimental
data to be presented before a test is licensed,
with people always being informed about
the reasons why a test is not available. This
would balance claims made by manufactur-
ers’ advertisements, which are often based
on preliminary studies.
The complexity of the issue is illustrated
particularly clearly in a numerical example
that an informed decision about testing for
prostate specific antigen might be based on.
The author reminds us that it is perfectly rea-
sonable to weigh up the pros and cons of
screening and conclude that it is a good thing
but that advocating a screening programme
to others implies an unequivocal benefit.
Birte Twisselmann technical editor
BMJ
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New European clinical trials
directive
Is European research possible?
Editor—The concerns expressed by the
signatories of the petition to save European
research are well founded, and the threats
foreseen are in the main real for academic
research as well as for smaller biotech and
pharmaceutical companies.1 2 At stake in the
EU directive on implementing good clinical
practice is the possibility of realising a Euro-
pean dimension to clinical research that has
the support of public confidence in the
research community.
The role and responsibilities of the
sponsor in clinical research are key issues.
The directive failed to tackle the complexity
of this issue in clinical trials. For the sake of
patients, the issue of sponsors’ responsibili-
ties needs to be settled throughout Euro-
pean research, with or without the support
of the directive.
The future health of Europe’s citizens
depends on the contributions of govern-
ment and non-government funded research
locally, nationally, and in Europe. Europe
cannot afford to lose the power and creativ-
ity of its academic researchers or the
possibilities offered by the smaller research
enterprises. The importance of academic
research for European health was not well
articulated in the debate that resulted in the
directive, with the exception of the steadfast
engagement of the European Organization
for Research and Treatment of Cancer.
European researchers need to decide
what they want to save. Do they wish to pool
their knowledge and resources in Europe?
Or do they prefer that research (as matters
now largely stand) be organised and
supported primarily nationally? The upshot
of the directive may be that national
research is strengthened.
The answers to the challenges do not lie
in the directive alone. Directive or no direc-
tive, the question is how to create a robust
European research environment that
ensures patient protection and public confi-
dence in all areas of health research.
Francis P Crawley secretary general
European Forum for Good Clinical Practice,
B-1040 Brussels, Belgium
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Implementation requires funding for
effective training programmes
Editor—The European Union’s clinical
trials directive has been the focus of much
attention in the clinical trials community, but
it has had little attention, and certainly much
less than it deserves, from the wider medical
community.1 Woods’s editorial clearly defines
the current state of play with this new legisla-
tion and its potential impact on non-
commercial or publicly funded research.2
Woods says that more research staff with
better professional training and support
may be needed in some publicly funded
research. This is in fact an absolute necessity.
The draft statutory instrument that will
transpose the EU directive into UK legisla-
tion lists more than 30 separate offences,
with penalties ranging from a substantial
fine to imprisonment.3 Since ignorance is no
defence in law, from 1 May investigators will
have to be aware of these new regulations.
Moreover, if NHS trusts and universities
are to become sponsors, as laid out in the
EU directive, they too must be aware of the
wide portfolio of responsibilities that will
accompany this role. What better way to
achieve this than by providing timely and
effective training programmes?
The scale of this task cannot be underes-
timated. Funding to develop training initia-
tives has not been readily forthcoming, and
we, like other groups who have a leading
role in this area, need support to facilitate
the implementation process. As part of the
better coordination called for by Woods
between the major stakeholders (investiga-
tors, funders, universities, and NHS organi-
sations), we recommend that funding for the
development of training initiatives be put
high on the agenda.
Allan Gaw director
Allan.Gaw@ctunit.co.uk
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Reconfiguration of surgical,
emergency, and trauma
services
Bigger is not better
Editor—Black’s editorial on the reconfigu-
ration of surgical, emergency, and trauma
services in the United Kingdom discusses
what is proving to be a destructive tendency
in Scottish medicine and, I suspect, in UK
medicine.1
A depressing trend prevails in Scotland
to see centralisation (sometimes euphemisti-
cally described as creating “managed clinical
networks”) as a reasonable solution to all the
ills that currently afflict us. These include the
new deal, the consultants’ contract, the gen-
eral practitioners’ contract, the European
Working Time Directive—all man-made
artefacts and all preoccupied with the
welfare of doctors, not patients.
A view dominates that unless something
can be done to the standard of the Mayo
Clinic it should not be done at all. This
endangers our small and not so small
district hospitals and our specialist services
in the regions of Scotland and ultimately
leads to the absurd conclusion that we have
only one or two hospitals.
We should instead be looking at how we
can improve medical services where our
people live. We have to do this to encourage
the survival and the development of our
regional and rural cultures. Fewer and
bigger hospitals are certainly not the answer.
Other European countries recognise that,
and I expect that our electorate will as well. If
they don’t some of us will be sure to tell
them.
David G Currie neurosurgeon
Aberdeen Royal Infirmary, Aberdeen AB25 2ZN
David.Currie@arh.grampian.scot.nhs.uk
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Patient power may be the way forward
Editor—The editorial by Black on the
reconfiguration of surgical and emergency
services in the United Kingdom exudes
common sense.1 Lomond in Scotland has
lost accident and emergency surgical serv-
ices in the past four months, and local
general practitioners have had difficulty in
securing safe services for the population.
This comes on top of loss of maternity
services last year at the local district general
hospital.
We have been badly served by surgeons
who, with their royal colleges, insist on
retreating to so called centres of excellence,
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with little thought of the price paid by the
population deprived of hospital services.
Administrators have no choice when sur-
geons cannot or do not have the will to think
“outside the box” for rural or small town
communities, but they could support gen-
eral practitioners trying to provide safe
cover for their patients.
Such support is not always forthcoming,
and general practitioners are left struggling
to provide a service with colleagues in the
ambulance service, themselves not
adequately consulted on proposed changes
and their effect on the locality. Important
groups such as the police are not even con-
sulted on proposed changes to local
emergency services.
Patients are waking up to the reality of
loss of services and are voting out politi-
cians, with examples in England, Scotland,
and Northern Ireland. In the west of
Scotland general practitioners are working
with patients’ groups, hospital consultants,
and ambulance staff to discuss how local
services can be delivered. Patient power has
delayed the closure of emergency and surgi-
cal services in Fort William, which may be
the way forward for coordinated action by
concerned communities.
Patrick M Trust principal in general practice
Medical Centre, Alexandria G83 0LS
patricktrust@ukonline.co.uk
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Recommendations are useful for
configuring emergency services in the
developing world
Editor—The editorial by Black on recon-
figuration of emergency services in the
United Kingdom is also important for the
developing world.1 Emergency services and
acute care constitute a major gap in the
focus of the health sector in the developing
world, and several issues need to be consid-
ered to promote a global dialogue on how
best to configure (rather than reconfigure)
such services.
Traditional investments in the health
sector in the developing world have been
biased towards urban areas, large tertiary
facilities, and specialty services to the
detriment of primary and acute care. This
bias needs to be addressed by ministries of
health and finance.
The use of non-doctor personnel is criti-
cal for the developing world. Shortages of
skilled staff, lack of training, and poorly
defined career structures plague human
resources in the health sector. It is time to
assess the potential contributions of other
health professionals for emergency care,
analogous to the community health workers
of primary health care.
Building infrastructure is important for
hospitals, clinics, and district facilities. Defin-
ing essential equipment and functions
seems like an appropriate task for agencies
such as the World Health Organization.
Capacity development for responding to
emergency is crucial. Training individual
doctors is not enough; emergency care
systems will need to be built to make a quan-
tum change in responding to the needs of
people.
It is time to recognise the great need for
acute care in the developing world and call
for more investment and efforts in building
appropriate systems. Maternal mortality,
cardiac deaths, and trauma should all be
manageable in the developing word, as in
the United Kingdom, by an appropriate
emergency medical system.
Adnan A Hyder assistant professor
Johns Hopkins Bloomberg School of Public Health,
615 North Wolfe Street, E-8132, Baltimore, MD
21205, USA
ahyder@jhsph.edu
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Data on neuraminidase
inhibitors were made available
Editor—In response to Symmonds et al,1 F
Hoffmann-La Roche would like to clarify
that data from studies WV15759/WV15871
were made available to the National Institute
for Clinical Excellence.
These were double blind, placebo
controlled trials, conducted in children aged
6 or older and 12 or younger, to investigate
the efficacy and tolerability of oseltamivir in
the treatment of influenza among asthmatic
children. Of the 355 children randomised to
treatment, 170 received oseltamivir 2 mg/kg
and 164 received placebo. Of these children,
179 had laboratory confirmed influenza
infection, which represented only 70% of the
planned recruitment target. This precluded
any statistical demonstration of the primary
efficacy end point “time to freedom from ill-
ness” (incorporating resolution of symptoms
and a return to normal activity).
Among the outcomes of this study, a
positive effect on forced expiratory volume
in one second in the oseltamivir group was
seen, an observation that is being further
investigated in an ongoing clinical trial in
asthmatic children. We would also like to
clarify that we plan to publish the results
from studies WV15759/WV15871.
Zoya Panahloo senior medical adviser, United
Kingdom
F Hoffmann La Roche, Welwyn Garden City,
Hertfordshire AL7 3AY
zoya.panahloo@roche.com
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Decline in mortality in children
with HIV in the UK and Ireland
Argument is flawed
Editor—The claims by Gibb et al, that their
evidence shows a decline in mortality of
children with HIV/AIDS in the United
Kingdom and Ireland (thanks to antiretro-
virals), cannot go unchallenged.1 In their
methods section they make little or no refer-
ence to the management of opportunistic
infections. Furthermore, we have no idea how
and where these children were delivered.
Were some of these children delivered by
caesarean section? This may be important
since some authors have asked whether the
protective effect of caesarean delivery inde-
pendent of zidovudine prophylaxis can be
further investigated by a large, international,
individual patient data meta-analysis of
observational studies. A definitive answer to
the question will require a randomised clini-
cal trial, which is the only method to ensure
that women who undergo an elective caesar-
ean delivery do not differ from those with
other types of delivery for any known or
unknown confounding factor.2
Sixty seven per cent of the children in
the paper by Gibb et al were of African par-
entage, but we are not given the dates when
their parents entered the United Kingdom.
Nutrition in Africa is known to be poor,
whereas in the United Kingdom it is better
and undoubtedly the immune status of these
children must have been boosted.
A worrying trend alluded to in this issue
of the BMJ is the decline in the number of
randomised controlled trials.3 Gibb et al
make no mention of this.
S W P Mhlongo chief specialist
ansie@wn.apc.org
P M H Maduna principal specialist
Department of Family Medicine and Primary
Health Care, Medunsa (Medical University of South
Africa) 0204, Pretoria, Gauteng
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HIV positive adolescents urgently need
dedicated services
Editor—Gibb et al describe the dramatic
impact of antiretroviral therapy in HIV-1
infected children.1 Improved survival means
that increasing numbers of HIV infected
adolescents will confront issues common to
this age group, such as poor outpatient
attendance,2 problems with adherence to
treatment,3 and transition to an adult
environment.
The Intercollegiate Working Party on
Adolescent Health supports the develop-
ment of dedicated adolescent clinics.4 In
2001 we established the first adolescent only
HIV outpatient service in the United
Kingdom. Young people were closely
involved in the multidisciplinary clinic
design, and a transition policy was devel-
oped together with the family unit at Great
Ormond Street Hospital.5 Our aim was to
create an environment where adolescents
felt able to discuss complex issues including
antiretroviral therapy, sexual debut, social
isolation, and familial bereavement.
Over the past two years 15 adolescents
have transferred to the clinic. Most (13) are
Black African. At the time of transition eight
had an AIDS defining illness, and 13
required antiretroviral therapy, eight with a
viral load < 50 copies/ml. Seven of the 14
adolescents who have ever taken antiretrovi-
rals have documented resistance to the
drugs, and four of the 15 report being
sexually active. No patients have been lost to
follow up.
Increasing numbers of HIV infected
children who have been treated with many
drugs are reaching adolescence and becom-
ing sexually active. We need dedicated
adolescent services to minimise loss to
follow up, encourage adherence to treat-
ment with antiretrovirals and prevent trans-
mission of drug resistant virus. As individual
HIV units see only small numbers of adoles-
cents, we should establish service networks
with comprehensive guidelines to ensure
best practice.
K P Prime specialist registrar, genitourinary medicine
katiaprime@hotmail.com
E A Jungmann consultant, genitourinary medicine
S G Edwards consultant, genitourinary medicine
Department of Genitourinary Medicine, Camden
Primary Care Trust, London WC1E 6AU
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Authors’ reply
Editor—Mhlongo and Maduna and Prime
et al challenge the results of our study and
think that we overlooked alternative reasons
for the rapid fivefold decline in mortality,
progression to AIDS, and hospital admis-
sion rates we reported in the CHIPS cohort
of vertically HIV infected children in the
United Kingdom and Ireland. We cannot
agree that they provide viable alternative
explanations for the dramatic reduction.
Firstly, we did not include details of
management of opportunistic infections,
and we agree that there is indirect evidence
that cotrimoxazole prophylaxis reduces the
frequency of these (particularly Pneumocystis
carinii pneumonia in infancy, as previously
reported in the United Kingdom1). This
does not explain the magnitude or the
timing of the effect we observed; cotrimoxa-
zole prophylaxis has been widely used in
HIV infected children in the United
Kingdom and Ireland since the early 1990s,
as evidenced by its inclusion in guidelines in
1994, which reflected established practice at
that time.2 No other significant change in the
management or prophylaxis of opportunis-
tic infections occurred around the time that
combination antiretroviral therapy became
available.
Secondly, we do not see the relevance of
including details on mode of delivery as our
paper related only to HIV infected children
(the authors seem unaware of the published
clinical trial that compared mother to child
transmission rates after elective caesarean
section v vaginal delivery3).
Thirdly, although we agree that the
nutritional status of children in the United
Kingdom and Ireland is much better than in
Africa, we were not comparing survival of
children in Africa with those here. Rather,
we included children in the analysis of our
cohort only after they had presented to
medical services in the United Kingdom or
Ireland (as detailed in the methods section).
If anything, there might have been a bias
towards poorer prognosis for the children
presenting in more recent years who were
more likely to be recent arrivals from Africa
with advanced symptomatic disease.
Finally, we did not discuss clinical trials
as our paper was about a cohort study. How-
ever, among paediatricians working with
HIV infected children there is a strong tradi-
tion of enrolling children in clinical trials
through the Paediatric European Network
for Treatment of AIDS (PENTA).
D M Gibb reader in epidemiology
mbh@ctu.mrc.ac.uk
T Duong statistician
Medical Research Council Clinical Trials Unit,
London NW1 2DA
P A Tookey senior lecturer in paediatric epidemiology
Centre for Paediatric Epidemiology and
Biostatistics, Institute of Child Health, London
WC1N 1EH
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Hospital, LondonW2 1NY; V Novelli, consultant
in paediatric infectious diseases, Great Ormond
Street Hospital for Sick Children NHS Trust,
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Hospital, Birmingham B9 5SS; L Farrelly, clinical
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research fellow, Centre for Paediatric Epidemiol-
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professor in epidemiology, both Institute of
Child Health, London WC1N 1EH; D T Dunn,
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National Study of HIV in Pregnancy and Child-
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Study (CHIPS).
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Treating major depression in
children and adolescents
Research is needed into safer and more
effective drugs
Editor—We report our preliminary findings
on prescribing of antidepressants in general
practice, in response to the recommendation
by the regulatory agency for medicines and
healthcare products to withdraw selective
serotonin reuptake inhibitors from use in
paediatric depression.1 2
We used the general practice research
database to analyse use between 1 January
1992 and 31 December 2001 (88 522
prescriptions issued to 23 999 children and
adolescents).3 Fifty nine per cent of antide-
pressant prescriptions were for tricyclics;
39% were for selective serotonin reuptake
inhibitors. The most commonly prescribed
antidepressants were imipramine (25% of
prescriptions), fluoxetine (19%), and
amitriptyline (18%). Paroxetine, sertraline,
citalopram, venlafaxine, and fluvoxamine
accounted for 21% of prescriptions. Sixty
three per cent, 35%, and 2% of patients were
given tricyclics, selective serotonin reuptake
inhibitors, and other antidepressants,
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respectively, as the first antidepressant
prescribed.
In patients aged 10 years or younger the
most commonly recorded indication for tri-
cyclic use was enuresis (78%); in those aged
15 years or older it was depression (53%). In
this older group, use of antidepressants was
three times more common in girls than
boys. In 1992 tricyclics were prescribed to
nine times more patients than selective sero-
tonin reuptake inhibitors; by 2001 twice as
many patients received selective serotonin
reuptake inhibitors than tricyclics.
Selective serotonin reuptake inhibitors
gained popularity for the treatment of
depression compared with tricyclics, but tri-
cyclics were used commonly in nocturnal
enuresis. These trends may change after the
recommendation. However, tricyclics are
ineffective in prepubertal depression, and
there is marginal evidence to support their
use in adolescents,4 leaving an urgent need
to research safer and more effective medi-
cines for children and adolescents with
depression.5
Macey L Murray research fellow
macey.murray@ulsop.ac.uk
Ian C K Wong director
Centre for Paediatric Pharmacy Research, School
of Pharmacy, University of London, London
WC1N 1AX
Corinne S de Vries senior lecturer
Department of Pharmacoepidemiology,
Postgraduate Medical School, University of Surrey,
Guildford GU2 7DJ
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Depressed adolescents may lose out
Editor—Ramchandani discusses the treat-
ment of major depressive disorder in
children and adolescents.1 The conclusion of
the Committee on Safety of Medicines is
based on two premises: lack of effectiveness
and increased risk of suicide.
None of the evidence stacks up. Even the
paper of the Food and Drug Administration
points out that the effectiveness of sertraline
and fluoxetine is likely to be the same.2
Furthermore, it says that in all the
organised trials, no completed suicide was
reported. It also points out that in major
depressive disease, suicide is a likely event
anyway. (In any case, the correct manage-
ment of depressed children entails suicide
watch.) If the risk increases it is likely to only
be at the beginning of treatment, when the
disinhibiting effects of selective serotonin
reuptake inhibitors are not yet balanced by
improving mood patterns.
What I find most unsatisfactory is the
failure to publish the data on which the con-
clusions are based. The Food and Drug
Administration concludes that the trials to
show effectiveness were possibly flawed and
inconclusive. This is an example of jumping
on the bandwagon of media scare stories,
and its likeliest effect is to increase morbidity
and suicide risk in children and adolescents.
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Use of selective serotonin reuptake
inhibitors needs urgent clarification
Editor—Ramchandani’s editorial focuses
entirely on the use of selective serotonin
reuptake inhibitors in the treatment of
major depressive disorder, just as did the
statements of the chairman of the Com-
mittee on Safety of Medicines on which he
comments.1 Did he not think it odd that the
statement said nothing about obsessive-
compulsive disorder, panic disorder, social
phobia, or general anxiety disorder, for
which various selective serotonin reuptake
inhibitors are also prescribed?
The committee does not say whether the
use of these drugs for these conditions in
people under 18 is justified and appropriate.
Presumably the committee’s expert working
group is considering these questions, but
that requires a clear official statement now.
The British National Formulary notes the
following indications2:
x Citalopram: panic disorder child not rec-
ommended (adolescent not mentioned)
x Escitalopram: child and adolescent under
18 not recommended (strange, since it is vir-
tually identical with citalopram)
x Fluoxetine: bulimia, obsessive-
compulsive disorder, child not recom-
mended (adolescent not mentioned)
x Fluvoxamine: obsessive-compulsive dis-
order, indicated for children over 8
x Paroxetine: obsessive-compulsive disor-
der, panic disorder, social phobia, general
anxiety disorder, child not recommended
(adolescent not mentioned)
x Sertraline: obsessive-compulsive disor-
der, indicated for children over 6 and
adolescents; post-traumatic stress disorder,
child not recommended (adolescent not
mentioned)
x Venlafaxine: general anxiety disorder,
child and adolescent under 18 not
recommended
It may be too late for the Committee on
Safety of Medicines and Medicines and
Healthcare Products Regulatory Agency to
unravel this confusion in time for the March
edition of the formulary, but that makes it
especially urgent for them to issue a clear
statement that will help prescribers, as well
as patients and their parents.
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Children and parents need
better information on
medicines
Editor—Bonati and Pandolfini write of the
need for a European formulary aimed at
helping those who prescribe for children or
who dispense for or give drugs to them.1
Better information about medicines for chil-
dren is certainly needed.
Most medicines are given to younger
children by parents and carers, whereas
older children generally self administer.
Since much of this is outside of current
licensed indications, very little information is
available to parents and children to help
themmake safe and informed choices about
medicine taking. Drug companies are
expressly prohibited from providing infor-
mation for the public about unlicensed use
of their products.
A new version ofMedicines for Children or
its equivalent is urgently needed, designed
for children and parents, and written in
clear, accessible lay language.2 Ideally this
would be available through the internet and
potentially via interactive television, as well
as in paper form. Such an innovation would
be a valuable resource for patients and for
health professionals, and would contribute
to the safer and more effective use of medi-
cines by children.
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